. . . . . . . . . . "Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 \u2013 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss."@en . . . . . . . . . . . . . . . "Etodolaco"@en . "1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid"@en . "Etodols\u00E4ure"@en . . . "Etodolac"@en . "Christopher A. Demerson, Leslie G. Humber, \"Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac.\" U.S. Patent US4585877, issued May, 1977."@en . . "* Oral cl=49.1 mL/h/kg [Normal healthy adults] * Oral cl=49.4 mL/h/kg [Healthy males (18-65 years)] * Oral cl=35.7 mL/h/kg [Healthy females (27-65 years)] * Oral cl=45.7 mL/h/kg [Eldery (>65 years)] * Oral cl=58.3 mL/h/kg [Renal impairement (46-73 years)] * Oral cl=42.0 mL/h/kg [Hepatic impairement (34-60 years)]"@en . "Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%."@en . "* 390 mL/kg"@en . "Terminal t_1/2, 7.3 ± 4.0 hours. Distribution t_1/2, 0.71 ± 0.50 hours"@en . "For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain."@en . "It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite."@en . "approved"@en . . . . . . . . . . . . . . . . . . . . "Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. "@en . . "Etodolacum"@en . "Take with food to reduce gastric irritation."@en . " "@en . . . "1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid"@en . . . . . . . . . . . . . . . "41340-25-4"@en . . . . "\u00C9todolac"@en . . . . . . . "1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid"@en . . . . . "investigational"@en . . . . . . "Avoid alcohol."@en . "Food increases the peak plasma concentration of extended-release tablets with no effect on extent of absorption."@en . . . . . . . . . . . . . . . . . . . . . . . "Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of etodolac. Etodolac may increase blood pressure and/or cause fluid retention and edema. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain."@en . . . . . . . . . . . . "Food increases the time to peak concentration of regular release oral formulations by 1.4 to 3.8 hours with no effect on extent of absorption. "@en . . "Etodolac"@en . . . "Etodolic acid"@en . "(+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid"@en . . . . . . . . . . . . . "Humans and other mammals"@en . . . "(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid"@en . . . "> 99% bound, primarily to albumin"@en . . .